Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Parkinson's Disease Market Snapshot (2023 to 2033)

The global Parkinson's disease market is expected to be worth US$ 3.7 billion in the fiscal year 2023. From 2023 to 2033, the global market is expected to grow at a steady 5.1% CAGR, reaching a value of US$ 6.1 billion by the end of 2033.

Parkinson's disease is a disorder of the brain that results in the death of nerve cells in a particular region of the brain. It affects a person in many different ways, including stiffness, sadness, memory issues, problems with coordination and balance, blood pressure, and thinking. Despite the fact that the ailment cannot be cured, there are several treatment options, including surgery, medications, and other therapies.

The major treatment for Parkinson's is levodopa. Levodopa is frequently used with the drug carbidopa to combat its many negative effects, including nausea, vomiting, lower blood pressure, and restlessness. The size of the market for treatments for Parkinson's disease is expanding as a result of evolving environmental variables and genetic predisposition

The high prevalence of Parkinson's Condition (PD) in western nations, the growing senior population, who are all at high risk for acquiring the disease, and the robust pipeline of disease-modifying medicines are all expected to be key business drivers. The International Parkinson and Movement Disorder Society estimates that 9.4 million people will have PD globally in 2020. Additionally, about 1% of people over the age of 60 are affected by PD, and that percentage jumps to 5% for people over the age of 85.

Additionally, recent advances and strategic actions by large or minor market participants are growing in both local and international markets. This is yet another important feature that will amplify the industry under study. For instance, Israel-based Pharma Two B Ltd. announced in December 2021 that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson's disease had successfully met its primary and important secondary endpoints. P2B001 was superior to each of its individual components as measured by the change in the total Unified Parkinson's Disease Rating Scale from baseline to week 12, which was the study's primary endpoint. P2B001 outperformed the pramipexole and rasagiline components, respectively, by 2.66 and 3.30 points, respectively (p=0.0018 and p=0.0001).

Attributes Details
Expected Market Value (2023) US$ 3.7 billion
Projected Forecast Value (2033) US$ 6.1 billion
Global Growth Rate (2023 to 2033) 5.1%
CAGR of North America (2023) 12.5%
CAGR of APAC (2023 to 2033) 12%
Prominent Players in The Global Market
  • Merck & Co., Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • Sawai Pharmaceutical Co., Ltd.
  • Novartis
  • Zydus Cadila
  • Intas Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals
  • Aurobindo Pharma Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lannett Company, Inc.
  • Accord Healthcare Ltd.
  • Morningside Pharmaceuticals Ltd.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Parkinson's Disease Market Demand Analysis Vs. Forecast 2023 to 2033

The global Parkinson's disease market grew at a CAGR of 6.8% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. The Covid-19 pandemic has had a significant effect on the market. The COVID-19 pandemic has relatively little of an impact on the world market for Parkinson's disease medications. The epidemic has had a direct influence on the supply and demand for Parkinson's medications, as well as on businesses and financial markets. It has also disturbed the distribution system.

The gradual increase in PD prevalence has opened the door for major pharmaceutical companies to pursue significant market expansion in this industry. For pharmaceutical firms, the availability of several dosage forms might enable product diversification, resulting in higher profitability. For the treatment of people with moderate-to-severe PD for whom oral medicines are no longer effective, NeuroDerm is developing ND0612.

Such factors are expected to boost the global sales of Parkinson's disease solutions. As a result, the global Parkinson's disease market is expected to forecast a CAGR of over 5.1% from 2023-2033.

Prominent Growth Drivers Influencing Parkinson's Disease Market

Continuous technological advances and research in this domain to boost the demand

Over the course of the analysis period, it is projected that ongoing developments in the Parkinson's disease drug category will drive market expansion. A research collaboration deal aimed at the discovery of novel biomolecular pre-clinical drug candidates for Parkinson's disease was signed in January 2022 by Iktos, a South Korean company that specializes in artificial intelligence (AI) for novel therapeutic design, and Astrogen, a medical and research-oriented biotech company aimed at developing new and innovative medications for the treatment of intractable neurodegenerative disorders.

Additionally, in March 2022, OrganoTherapeutics, a developer of patented technology patient-specific organoids that recapitulate Parkinson's Disease (PD) pathology, and Vyant Bio, Inc., an innovative biotechnology company concentrated on reinventing drug development for complex neurodevelopmental and neurodegenerative abnormalities, entered into a joint collaboration to work toward speeding up drug discovery. Such factors are sure to propel the market for Parkinson's disease during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

The manufacturer's robust pipeline of pharmaceuticals will provide attractive prospects for the Parkinson's disease industry to flourish

New product introductions in the worldwide market for Parkinson's disease therapy will help the industry develop to its full potential. For example, Adamas Pharmaceuticals, Inc. revealed subgroup analyses of Parkinson's disease patients receiving amantadine immediate release (IR) who are still suffering dyskinesia and are recruited in the long-term EASE LID 2 trial in February 2018.

The current phase 3 open-label research of GOCOVRITM (amantadine) extended-release capsule data reveals that motor applications increase by roughly 35%. This patient's tolerability and safety profile were found to be consistent, with no side effects. Furthermore, the majority of the big companies have an extensive therapeutic pipeline for Parkinson's disease treatment. Such developments are expected to accelerate the demand for Parkinson's disease during the forecast period.

What Could Possibly Hinder Parkinson's Disease Market Demand?

Discovery of various alternative treatments to impede the global market

Alternative medical therapies will have a significant influence on the worldwide Parkinson's disease industry. Alternative treatment methods and alternative items will face fierce competition from companies producing the same medicine. This will make it difficult for the producer to expand and offer other products on the market for the same type of sickness.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Region-wise Analysis

What is the outlook of the North American Parkinson's disease market?

High prevalence among the aging population to boost the regional demand

North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for Parkinson's disease, with a dominant 12.1% CAGR from 2023 to 2033.

The factors that lead to regional expansion involve very prevalent Parkinson's disease groups. Furthermore, the high prevalence found in the aging population fuels the growth of the Parkinson's disease market in North America. In the United States, almost 1 Billion people have Parkinson's disease. According to Parkinson's Foundation figures, this amount is significantly more than the total number of persons diagnosed with multiple sclerosis as well as muscular dystrophy.

The overall direct and indirect expenses of Parkinson's disease, including treatment, social payments, and lost income, are estimated to be about US$ 52 billion per year in the United States alone. Furthermore, the Parkinson's Prevalence Project predicts that 930,000 persons in the United States will have Parkinson's disease (PD) by 2020. This figure is estimated to reach 1.2 Billion by the year 2030. Hence, there would be a lot of scope for North American manufacturers to develop in this market during the forecast period.

What can be expected from the APAC market for Parkinson's disease?

Large patient pool and more research and awareness programs to propel the sales

During the forecast period, the APAC market for Parkinson's disease is expected to garner a steady CAGR of 12%. But at the time, this market is presently acquiring 31% market share in the global Parkinson's disease market.

The emergence of a larger number of generic manufacturers as well as substantial market prospects for Parkinson's disease, notably in China, India, and Japan, will eventually drive the geographical expansion of the Asia-Pacific Parkinson's disease market.

The region is also seeing growth as a result of expanded product penetration, untapped potential, and the rising prevalence of Parkinson's disease in emerging nations. For example, UCB S.A. got an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) in July 2022 to supply and distribute Neupro in China. Neupro is suggested as monotherapy in conjunction with levodopa for the treatment of people with early-stage idiopathic Parkinson's disease. Such developments are expected to accelerate the growth in the market from 2023 to 2033.

Category-wise Insights

Which drug class type segment is expected to gain traction from 2023 to 2033?

The Carbidopa-levodopa drug class segment will gain the dominant market share

Over the course of the forecast period, the Carbidopa-levodopa segment by drug class is anticipated to occupy a significant share of the global Parkinson's disease market. In 2023, this category is anticipated to dominate with a 32% revenue share.

The high incidence of these medications' prescriptions was thought to be the cause of this rise. According to the US Drug Use Statistics, 183,670 Parkinson's patients are expected to receive 527,540 prescriptions for carbidopa-levodopa in 2021.

Combinations of the drugs carbidopa along with levodopa are used to treat Parkinson's disease (PD) symptoms. It is the most effective drug for PD and is frequently used as a second line of therapy. It can be taken largely orally, for example, as immediate-release pills, controlled-release tablets, enteral solution, or extended-release capsules.

Additionally, the existence of pipeline candidates like LY03003 and an increase in the market for dopamine agonists are elements that are anticipated to favorably contribute to segmental growth. Such factors are expected to accelerate the growth prospects for Parkinson's disease from 2023 to 2033.

What would be the outlook of the age segment?

The adult segment will become more significant from 2023 to 2033

On the basis of the age type, the other dominant segment is the adult segment, which is expected to occupy a global market share of 21% from 2023 to 2033.

According to the journal article "Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future" released in February 2022, there are an estimated 6.1 Billion people worldwide who have Parkinson's disease. The prevalence rises with age, reaching from 1% to 3% in people over 65.

Additionally, UN research estimates that 727 Billion people worldwide would be 65 years of age or older in 2020. In addition, it is anticipated that by 2050, there will be twice as many people worldwide who are 80 years of age or older.

Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 persons worldwide would be 60 years of age or older by the year 2030. Consequently, it is projected that there will be a demographic change as the world's geriatric population rises. The rise in older adults is anticipated to accelerate market growth over the study period.

Start-up Scenario

The start-ups want to differentiate their products on the worldwide market by adding new technology and improved safety features to their products. They are first concentrating on reducing the symptoms. Some of the businesses include:

  • The American company Skyhawk's Therapeutics is creating small-molecule therapeutics which correct RNA expression. Their unique approach makes it possible to create tiny compounds that target specific RNA splicing procedures. They are now working on drug options for neurological disorders, cancer, and other rare diseases.
  • Cala Health is a healthcare technology company that is pioneering a new form of electrical medicine known as neuro peripheral treatment. By using electronics placed on the body to externally stimulate peripheral nerves, neuro peripheral treatment offers the potential to treat chronic diseases. Experts from the fields of neurology, consumer electronics, as well as medical technologies are being brought together by Cala Health to provide affordable, non-invasive treatments for chronic diseases. Such treatments can be highly effective for the treatment of the symptoms of Parkinson's disease.

Competitive Landscape

Some of the prominent players in the global market for Parkinson's disease are:

  • Merck & Co., Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • Sawai Pharmaceutical Co., Ltd.
  • Novartis
  • Zydus Cadila
  • Intas Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals
  • Aurobindo Pharma Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lannett Company, Inc.
  • Accord Healthcare Ltd.
  • Morningside Pharmaceuticals Ltd.

Some of the prominent developments of the key players in the market are:

  • Rusan Pharma announced the availability of a Parkinson's disease treatment in December 2018. The medicine 'Aposan' is used to monitor variations in Parkinson's disease patients who are not adequately managed by oral treatments currently available in the Indian market.
  • Biogen announced cooperation with Denali upon the LRRK2 program for Parkinson's disease and specific TV platform-enabled neurodegenerative disease initiatives in August 2020. They have agreed to collaborate on the development and commercialization of Denali's small-molecule inhibitors of leucine-rich repetitive kinase 2 (LRRK2) for Parkinson's disease. Biogen will also acquire the opportunity to opt into two projects and the first right of refusal for two more studies, all of which will be for neurodegenerative disorders that will use Denali's Transport Vehicle (TV) software company to breach the blood-brain barrier.

Value-added Insights:

  • Disease Epidemiology
  • Patient Treatment Journey
  • Product Adoption Analysis, By Region
  • New Product Launches and Approvals
  • Regulatory Scenario, By Key Countries
  • Reimbursement Scenario, By Key Countries
  • Porter’s Analysis
  • PESTLE Analysis
  • Market Entry Barriers
  • Supply Chain Assessment 
  • Pipeline Assessment 

By Phase
By Drug Class
By Company

Key Segments Covered In The Parkinson's Disease Market Report

By Drug Class:

  • Levodopa

50 mg levodopa combined with 12.5 mg carbidopa
100 mg levodopa combined with 25 mg carbidopa
100 mg levodopa combined with 10 mg carbidopa
200 mg levodopa combined with 50 mg carbidopa
250 mg levodopa combined with 25 mg carbidopa

  • Dopamine agonists

0.125 mg
0.25 mg
1.5 mg
5 mg

  • MAO-B inhibitors

0.5 mg
1 mg
1.25 mg
2.5 mg
5 mg
10 mg

  • COMT inhibitors

100 mg
200 mg

  • Others

By Form:

  • Oral

Oral Ordinary (immediate release, oral disintegrating, oral solution)
Oral Long Acting (extended release)

  • Injectable

Pre-filled Syringes
Vials

  • Inhalation
  • Others (patches, films)

By Brand:

  • Branded
  • Generics

By Distribution Channels:

  • Institutional Sales

Hospitals
Specialty Clinics
Others

  • Retail Sales

Retail Pharmacies
Drug Stores
Online Pharmacy

Frequently Asked Questions

At what rate did the Parkinson's disease market flourish from 2018 to 2022?

During the historical period of 2018 to 2022, the Parkinson's disease market grew at a CAGR of 6.8%.

What will be the growth rate of the global Parkinson's disease market during the forecast period?

The global Parkinson's disease market is predicted to rise with a steady 5.1% CAGR from 2023 to 2033.

What is the present market value of the Parkinson's disease market?

The global Parkinson's disease market is currently worth more than US$ 3.7 billion.

What will be the projected market size of the Parkinson's disease market by 2033?

By 2033, the global Parkinson's disease market is projected to reach a market size of US$ 6.1 billion.

Which segment is expected to dominate the global Parkinson's disease market during 2023?

In 2023, the Carbidopa-levodopa segment by drug class type is anticipated to dominate with a 32% revenue share.

What will be the outlook of the other segment during the forecast period?

The adult segment by age type will occupy the second largest segment during the forecast period with a 21% market share in 2023.

How is the North American Parkinson's disease market projected to grow during 2023 to 2033?

The North American region is predicted to grow with a steady CAGR of 12.5% from 2023 to 2033.

What is the outlook of the APAC Parkinson's disease market during 2023?

The APAC Parkinson's disease market is expected to grow with a steady CAGR of 12% from 2023 to 2033.

Table of Content

1. Executive Summary | Parkinson's Disease Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Juvenile Parkinson's Disease

        5.3.2. Young-onset Parkinson’s Disease

        5.3.3. Idiopathic Parkinson's Disease

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Age, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age, 2023 to 2033

        6.3.1. Adult

        6.3.2. Pediatric

    6.4. Y-o-Y Growth Trend Analysis By Age, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Age, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033

        7.3.1. CT Scan

        7.3.2. MRI Scan

        7.3.3. DaTSCAN-SPECT scan

        7.3.4. PET Scan

    7.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        8.3.1. Carbidopa-levodopa

        8.3.2. Carbidopa-levodopa infusion

        8.3.3. Dopamine Agonists

        8.3.4. Monoamine Oxidase B Inhibitors

        8.3.5. Catechol O-methyltransferase Inhibitors

        8.3.6. Anticholinergics

        8.3.7. Amantadine

    8.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. Asia-Pacific

        9.3.6. Middle East & Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. The US

            10.2.1.2. Canada

        10.2.2. By Type

        10.2.3. By Age

        10.2.4. By Diagnosis

        10.2.5. By Drug Class

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Age

        10.3.4. By Diagnosis

        10.3.5. By Drug Class

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Type

        11.2.3. By Age

        11.2.4. By Diagnosis

        11.2.5. By Drug Class

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Age

        11.3.4. By Diagnosis

        11.3.5. By Drug Class

    11.4. Key Takeaways

12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Benelux

            12.2.1.2. France

            12.2.1.3. Germany

            12.2.1.4. Italy

            12.2.1.5. Nordic

            12.2.1.6. Spain

            12.2.1.7. The UK

            12.2.1.8. Rest of Western Europe

        12.2.2. By Type

        12.2.3. By Age

        12.2.4. By Diagnosis

        12.2.5. By Drug Class

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Age

        12.3.4. By Diagnosis

        12.3.5. By Drug Class

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Rest of Eastern Europe

        13.2.2. By Type

        13.2.3. By Age

        13.2.4. By Diagnosis

        13.2.5. By Drug Class

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Age

        13.3.4. By Diagnosis

        13.3.5. By Drug Class

    13.4. Key Takeaways

14. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Malaysia

            14.2.1.3. Singapore

            14.2.1.4. Thailand

            14.2.1.5. Australia

            14.2.1.6. New Zealand

            14.2.1.7. Rest of APAC

        14.2.2. By Type

        14.2.3. By Age

        14.2.4. By Diagnosis

        14.2.5. By Drug Class

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Age

        14.3.4. By Diagnosis

        14.3.5. By Drug Class

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Type

        15.2.3. By Age

        15.2.4. By Diagnosis

        15.2.5. By Drug Class

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. By Age

        15.3.4. By Diagnosis

        15.3.5. By Drug Class

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. The US

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Type

            16.1.2.2. By Age

            16.1.2.3. By Diagnosis

            16.1.2.4. By Drug Class

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Type

            16.2.2.2. By Age

            16.2.2.3. By Diagnosis

            16.2.2.4. By Drug Class

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Type

            16.3.2.2. By Age

            16.3.2.3. By Diagnosis

            16.3.2.4. By Drug Class

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Type

            16.4.2.2. By Age

            16.4.2.3. By Diagnosis

            16.4.2.4. By Drug Class

    16.5. Benelux

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Type

            16.5.2.2. By Age

            16.5.2.3. By Diagnosis

            16.5.2.4. By Drug Class

    16.6. France

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Type

            16.6.2.2. By Age

            16.6.2.3. By Diagnosis

            16.6.2.4. By Drug Class

    16.7. Germany

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Type

            16.7.2.2. By Age

            16.7.2.3. By Diagnosis

            16.7.2.4. By Drug Class

    16.8. Italy

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Type

            16.8.2.2. By Age

            16.8.2.3. By Diagnosis

            16.8.2.4. By Drug Class

    16.9. Nordic

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Type

            16.9.2.2. By Age

            16.9.2.3. By Diagnosis

            16.9.2.4. By Drug Class

    16.10. Spain

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Type

            16.10.2.2. By Age

            16.10.2.3. By Diagnosis

            16.10.2.4. By Drug Class

    16.11. The UK

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Type

            16.11.2.2. By Age

            16.11.2.3. By Diagnosis

            16.11.2.4. By Drug Class

    16.12. Poland

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Type

            16.12.2.2. By Age

            16.12.2.3. By Diagnosis

            16.12.2.4. By Drug Class

    16.13. Russia

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Type

            16.13.2.2. By Age

            16.13.2.3. By Diagnosis

            16.13.2.4. By Drug Class

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Type

            16.14.2.2. By Age

            16.14.2.3. By Diagnosis

            16.14.2.4. By Drug Class

    16.15. Malaysia

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Type

            16.15.2.2. By Age

            16.15.2.3. By Diagnosis

            16.15.2.4. By Drug Class

    16.16. Singapore

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Type

            16.16.2.2. By Age

            16.16.2.3. By Diagnosis

            16.16.2.4. By Drug Class

    16.17. Thailand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Type

            16.17.2.2. By Age

            16.17.2.3. By Diagnosis

            16.17.2.4. By Drug Class

    16.18. Australia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Type

            16.18.2.2. By Age

            16.18.2.3. By Diagnosis

            16.18.2.4. By Drug Class

    16.19. New Zealand

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Type

            16.19.2.2. By Age

            16.19.2.3. By Diagnosis

            16.19.2.4. By Drug Class

    16.20. GCC Countries

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Type

            16.20.2.2. By Age

            16.20.2.3. By Diagnosis

            16.20.2.4. By Drug Class

    16.21. South Africa

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Type

            16.21.2.2. By Age

            16.21.2.3. By Diagnosis

            16.21.2.4. By Drug Class

    16.22. Israel

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Type

            16.22.2.2. By Age

            16.22.2.3. By Diagnosis

            16.22.2.4. By Drug Class

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Type

        17.3.3. By Age

        17.3.4. By Diagnosis

        17.3.5. By Drug Class

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Sunovion Pharmaceuticals

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Adamas Pharmaceuticals

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Neurocrine Biosciences

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Supernus Pharmaceuticals

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Kyowa Kirin

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. AbbVie

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Integrative Research Laboratories AB

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Annovis Bio Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Cerevel Therapeutics

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. AMillioneal Pharmaceuticals

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Neurodegenerative Disease Market

Published : May 2024

Healthcare

Autoimmune Disease Therapeutics Market

Published : July 2023

Healthcare

Infectious Disease Diagnostics Market

Published : November 2022

Explore Healthcare Insights

View Reports

Parkinson's Disease Market